Eli Lilly (LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Eli Lilly (NYSE:LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Outside of the core registrational programs for these two important indications, we have several additional ongoing phase ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...